Voyager Therapeutics, Inc. (VYGR) — SEC Financial Statements & Analysis

Voyager Therapeutics, Inc. (VYGR) is a biological products, (no diagnostic substances) company, incorporated in DE. Voyager Therapeutics, Inc. trades on Nasdaq as: VYGR. Voyager Therapeutics, Inc. (VYGR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Voyager Therapeutics, Inc. carries a market cap of $211.92M, a P/E ratio of -1.97x, a P/B ratio of 1.37x, a P/S ratio of 6.15x, an enterprise value of $173.41M, and an EV/EBITDA multiple of -1.53x. On profitability, it posts an operating margin of -340.08%, a net margin of -312.63%, a Return on Equity (ROE) of -54.09%, a Return on Assets (ROA) of -41.45%, and a Return on Invested Capital (ROIC) of -74.51%. Per share, it reports EPS of $-1.78, diluted EPS of $-1.78, free cash flow per share of $-2.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -19.07% year-over-year, net income growth of -0.19% year-over-year, and EPS growth of -3.29% year-over-year. On the balance sheet, it maintains a current ratio of 7.51x, a quick ratio of 7.16x, working capital of $108.54M, a debt-to-equity ratio of 0.28x, a debt ratio of 0.22, an interest coverage ratio of -14.77x, free cash flow of $-121.42M (TTM), and net debt of $-38.51M. Figures sourced from SEC EDGAR.

Market Cap

$211.92M

P/E TTM

-1.97x

EPS TTM

$-1.78

P/B TTM

1.37x

ROE TTM

-54.09%

ROA TTM

-41.45%

Debt To Equity

0.28x

Free Cash Flow TTM

$-121.42M

Net Revenue TTM Growth 1Y

-19.07%

Data as of 2026-06-30 · Source: SEC EDGAR